Evidence map›Paper›PMID 38778515›Full record

ArticleCPT: pharmacometrics & systems pharmacology2024

A novel Bayesian generative approach for estimating tumor dynamics from published studies.

Arya Pourzanjani, Saurabh Modi, Jamie Connarn, Xinwen Zhang, Vijay Upreti, Chih-Wei Lin, Khamir Mehta

Abstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Arya PourzanjaniClinical Pharmacology Modeling & Simulation (CPMS) Department, Amgen Inc., South San Francisco, California, USA.ORCID 0000-0002-9613-4139
Saurabh ModiClinical Pharmacology Modeling & Simulation (CPMS) Department, Amgen Inc., South San Francisco, California, USA.ORCID 0000-0003-1269-8971
Jamie ConnarnClinical Pharmacology Modeling & Simulation (CPMS) Department, Amgen Inc., South San Francisco, California, USA.ORCID 0000-0001-7112-7357
Xinwen ZhangClinical Pharmacology Modeling & Simulation (CPMS) Department, Amgen Inc., South San Francisco, California, USA.ORCID 0000-0001-5616-4846
Vijay UpretiClinical Pharmacology Modeling & Simulation (CPMS) Department, Amgen Inc., South San Francisco, California, USA.ORCID 0000-0003-1018-7166
Chih-Wei LinClinical Pharmacology Modeling & Simulation (CPMS) Department, Amgen Inc., Thousand Oaks, California, USA.
Khamir MehtaClinical Pharmacology Modeling & Simulation (CPMS) Department, Amgen Inc., South San Francisco, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor growth inhibition (TGI) modeling attempts to describe the time course changes in tumor size for patients undergoing cancer therapy. TGI models present several advantages over traditional exposure-response models that are based explicitly on clinical end points and have become a popular tool in the pharmacometrics community. Unfortunately, the data required to fit TGI models, namely longitudinal tumor measurements, are sparse or often not available in literature or publicly accessible databases. On the contrary, common end points such as progression-free survival (PFS) and objective response rate (ORR) are directly derived from longitudinal tumor measurements and are routinely published. To this end, a Bayesian generative model relating underlying tumor dynamics to summary PFS and ORR data is introduced to learn TGI model parameters using only published summary data. The parameterized model can describe the tumor dynamics, quantify treatment effect, and account for differences in the study population. The utility of this model is shown by applying it to several published studies, and learned parameters are combined to simulate an in silico trial of a novel combination therapy in a novel setting.

Indexed as

Bayes TheoremNeoplasmsAntineoplastic AgentsComputer SimulationHumansModels, BiologicalProgression-Free SurvivalAntineoplastic Agents

Identifiers

PMID38778515
PMCPMC11330188

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.